Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc. (PBLA) Stock Overview
Explore Panbela Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
971K
P/E Ratio
-0.03
EPS (TTM)
$-34.51
ROE
3.05%
PBLA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Panbela Therapeutics, Inc. (PBLA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 46.79, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.04.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.03 and a market capitalization of 971K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Jennifer K. Simpson CRNP, M.S.N.,
7
712 Vista Boulevard, Waconia, MN
2017